In Good Company with Nicolai Tangen HIGHLIGHTS: David Ricks - CEO of Eli Lilly
18 snips
Feb 21, 2025 David Ricks, Chair and CEO of Eli Lilly, discusses the groundbreaking advances in weight-reducing drugs that extend their benefits beyond initial intentions, like treating addiction and Alzheimer's. He highlights how Eli Lilly has halved drug development timelines through innovative approaches and AI. Ricks also navigates the challenges of drug pricing ethics in different markets, emphasizing the balance between patient access and business sustainability. This conversation reveals the exciting future of medicine and its transformative potential.
AI Snips
Chapters
Transcript
Episode notes
GLP-1 Drug Development
- Eli Lilly's GLP-1 drugs are not a new concept, with the first agonist launched in 2006.
- The effectiveness of these drugs has increased over time with advancements in molecular technology, culminating in the dual-acting Trisepetide.
Weight Loss: A Positive Surprise
- Weight reduction was initially a positive side effect of GLP-1 drugs rather than the primary goal.
- The 2007 annual report even featured a patient who highlighted the weight loss benefit.
The Future of Weight Management
- GLP-1 drugs impact the brain's desire center, potentially addressing behavioral issues like addiction.
- Weight management could become a choice rather than an affliction, and these drugs could significantly reduce chronic disease costs.